Overview

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

Status:
Active, not recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company